CHIRHOSTIM
LOE Approachinghuman secretin
NDAINTRAVENOUSFOR SOLUTIONPriority Review
Approved
Apr 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
Priority Review
CHIRHOSTIM (human secretin) is mechanism of action 12. First approved in 2004.
Drug data last refreshed 3d ago
Mechanism of Action
Mechanism of Action 12.1 Mechanism of Action The primary action of ChiRhoStim is to stimulate pancreatic ductal cells to secrete pancreas fluid in large volumes that contain bicarbonate. Secretin is a hormone that is normally released from the duodenum upon exposure of the proximal intestinal lumen…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas
Started Mar 2008
258 enrolled
Pancreatitis
Synthetic Human Secretin in Children With Autism
Started Apr 2002
Autism
Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
Started Apr 2002
Autism
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.